HTG Overview Video
HTG’s proprietary RNA technologies are designed to help better understand disease and treatment options for patients and to unlock a disruptive approach to drug discovery.
News & Events
WIN Consortium to Launch New Precision Oncology Study, Bank Samples for Blood Biomarker Discovery
The Worldwide Innovative Networking (WIN) Consortium at its annual symposium this week provided an update on its precision oncology clinical trial pipeline.
HTG and Red Nose Day!
HTG is proud to support Red Nose Day and we’re doing our part to end child hunger.
Two Tucson biotechs honored for fast-lane growth
Calimmune Inc. and HTG Molecular Diagnostics Inc. of Tucson will be joined by Phoenix-based VisionGate Inc. and recognized at the AZBio Awards on Oct. 1 at the Phoenix Convention Center. HTG Molecular has commercialized its HTG Edge instrument platform and a portfolio of gene-based tests using its proprietary, RNA-based technology.
Making LIFE Better: HTG Molecular Diagnostics receives AZBio Fast Lane Honors
In recognition of its contribution to new innovations and tools in the field of molecular diagnostics for the advancement of precision medicine, HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) has been named a 2015 AZBio Fast Lane Company by the Arizona Bioindustry Association (AZBio).
HTG Molecular Launches NGS-based microRNA Assay; Additional RNA, DNA Assays to Follow
NEW YORK (GenomeWeb) – HTG Molecular Diagnostics has entered the next-generation sequencing space with the launch of its first assay, which targets and sequences 2,275 microRNAs using its proprietary nuclease protection probe technology.
- Category:
- News
Ovagene Deal Highlights HTG Molecular’s Strategy of Being Platform Provider for MDx Firms
HTG Molecular announced a deal with Ovagene Oncology this week that will see Ovagene adopt HTG’s Edge System for its menu of gynecological cancer-focused tests.
HTG Molecular to File Edge System with US, European, Canadian Agencies for Dx Use by Year End
HTG Molecular is preparing a triad of submissions for its Edge System in the US, EU, and Canada, a company executive said this week.
PROOF for FFPE samples | Drug Discovery News
TUCSON, Ariz.—HTG Molecular Diagnostics and the Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) have finalized a license agreement that provides HTG exclusive rights to commercialize PROOF Centre-developed gene expression blood tests to evaluate the prognosis of chronic obstructive pulmonary disease (COPD) patients who are likely to experience frequent exacerbations known as lung attacks.
HTG working on radiation-exposure testing | Arizona Daily Star
After a major nuclear accident, identifying early on which victims were zapped with the most radiation could help save lives.
Spanning the melanoma continuum | Drug Discovery News
TUCSON, Ariz.—HTG Molecular Diagnostics is collaborating with the John Wayne Cancer Institute (JWCI) to market its melanoma signature assays.
HTG, Sanofi Collaborating to Identify B- Cell Response Markers for Cancer Drug | GenomeWeb
A biomarker discovery collaboration between HTG Molecular Diagnostics and Sanofi US will use HTG’s quantitative nucleic acid protection, or qNPA, technology to identify molecular targets in white blood cells associated with response to an unnamed cancer drug.
Page last updated March 20, 2023